<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: In patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, insulin therapy is commonly initiated with either a single dose of basal insulin or twice-daily premixed (basal plus prandial) insulin despite no widely accepted recommendation </plain></SENT>
<SENT sid="1" pm="."><plain>We compared the glycaemic control, as measured by a change in HbA1c, of intensive mixture therapy (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e>), a basal plus prandial regimen using insulin lispro mixture 50/50 (50% lispro and 50% NPL) before breakfast and lunch and insulin lispro mixture 25/75 (25% lispro and 75% NPL) before dinner, vs. once-daily insulin glargine therapy, while continuing patients on oral antidiabetes medications </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Following inadequate glycaemic control (HbA1c 1.2-2.0 times the upper limit of <z:mpath ids='MPATH_458'>normal</z:mpath>) and at least 2 months of two or more oral antidiabetes agent therapy, 60 insulin-na√Øve patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> were randomized to one of the insulin regimens for 4 months with crossover to the alternative regimen for an additional 4 months </plain></SENT>
<SENT sid="3" pm="."><plain>Glycaemic goals were preprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> &lt;120 mg/dl (6.7 mmol/l) and 2-h postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> &lt;180 mg/dl (10.0 mmol/l) </plain></SENT>
<SENT sid="4" pm="."><plain>The insulin dose was optimized by investigators without forced titration </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Mean prestudy (baseline) HbA1c for <z:hpo ids='HP_0000001'>all</z:hpo> patients was 9.21 +/- 1.33% (+/-s.d.) </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> compared to glargine resulted in both a lower endpoint in HbA1c (7.08 +/- 0.11% vs. 7.34 +/- 0.11%; p = 0.003) and a greater change in HbA1c from pretherapy (-1.01 +/- 0.10% vs. -0.75 +/- 0.10%; p = 0.0068) </plain></SENT>
<SENT sid="7" pm="."><plain>Forty-four per cent of patients receiving <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> and 31% of patients receiving insulin glargine achieved HbA1c &lt; or = 7% </plain></SENT>
<SENT sid="8" pm="."><plain>Two-hour postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> values (for <z:hpo ids='HP_0000001'>all</z:hpo> three meals) and predinner <z:chebi fb="105" ids="17234">glucose</z:chebi> values were significantly less with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> than with insulin glargine (p = 0.0034, 0.0001, 0.0066 and 0.0205) </plain></SENT>
<SENT sid="9" pm="."><plain>Overall <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> throughout the complete treatment period was infrequent (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> vs. Glargine: 3.98 +/- 4.74 vs. 2.57 +/- 3.22 episodes/patient/30 days, p = 0.0013), and no severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> was observed during the study with either therapy </plain></SENT>
<SENT sid="10" pm="."><plain>There was no difference in nocturnal <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> between the two therapies </plain></SENT>
<SENT sid="11" pm="."><plain>The mean insulin dose at the end of therapy was greater for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> than for once-daily insulin glargine (0.353 +/- 0.256 vs. 0.276 +/- 0.207 IU/kg, p = 0.0107) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: In combination with oral antidiabetes agents, multiple daily injections of a basal plus prandial insulin <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> regimen (using premixed insulin lispro formulations) resulted in greater improvements and a lower endpoint in HbA1c compared with a basal-only insulin regimen </plain></SENT>
<SENT sid="13" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> also resulted in improved postprandial blood <z:chebi fb="105" ids="17234">glucose</z:chebi> control at each meal and enabled administration of a greater daily dose of insulin, which most likely contributed to these lower HbA1c measures </plain></SENT>
<SENT sid="14" pm="."><plain>This greater reduction in HbA1c with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">IMT</z:e> is accompanied by a small increased occurrence of mild <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> but without any severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="15" pm="."><plain>Greater consideration should be given to initiating insulin as a basal plus prandial regimen rather than a basal-only regimen </plain></SENT>
</text></document>